Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Scientists track drug behavior in severe colitis patients

NCT ID NCT03765450

First seen Jun 10, 2026 · Last updated Jun 19, 2026 · Updated 1 time

Summary

This study looks at how the drug infliximab behaves in the body of people hospitalized with severe ulcerative colitis. Researchers measure drug levels in blood, stool, and colon tissue, along with changes in proteins and genes. The goal is to better understand how the drug works, not to test a new treatment. About 18 adults with severe colitis are taking part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE SEVERE ULCERATIVE COLITIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Cornell University

    New York, New York, 10065, United States

  • Mount Sinai Hospital

    Toronto, Ontario, M5G 1X5, Canada

  • UCSD

    San Diego, California, 92037, United States

Conditions

The condition(s) this trial relates to.

ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.